Initiate Treatment with Fluvoxamine
|
Thirty patients with GSAD were treated with fluvoxamine, 50 to 150 mg/d, in a randomized double-blind, placebo-controlled study during 12 weeks by van Vliet et al. Fluvoxamine was statistically superior to placebo on all outcome measures. In the study, 46% of the fluvoxamine-treated patients and 7% of placebo patients were deemed responders.
Sarah J. Thompson, MD
Online Diagnosis of Symptoms and Medical Diseases Online Diagnosis of Psychiatric Disorders
Online treatment advisor for medical and psychiatric disorders
|